Although higher ANO1 expression is associated with worse OS and DFS, an in vitro model of HNSCC demonstrated that overexpression of ANO1 in Te11 cells was linked with enhanced sensitivity to EGFR-targeted agent, Gefitinib, making ANO1 a good predictive biomarker and potential target for EGFR-directed therapy [42]. The gene discussed is ANO1; the disease is head and neck squamous cell carcinoma.